MCID: SRC027
MIFTS: 58

Sarcoma, Synovial

Categories: Genetic diseases, Rare diseases, Cancer diseases

Aliases & Classifications for Sarcoma, Synovial

MalaCards integrated aliases for Sarcoma, Synovial:

Name: Sarcoma, Synovial 53 13 13 41
Synovial Sarcoma 12 72 49 55 36 28 69 14
Synovialosarcoma 55
Sarcoma Synovial 51

Characteristics:

Orphanet epidemiological data:

55
synovial sarcoma
Inheritance: Not applicable; Age of onset: All ages;

HPO:

31
sarcoma, synovial:
Inheritance somatic mutation


Classifications:



External Ids:

OMIM 53 300813
Disease Ontology 12 DOID:5485
MeSH 41 D013584
NCIt 46 C3400
SNOMED-CT 64 302851001 63211008
Orphanet 55 ORPHA3273
UMLS via Orphanet 70 C0039101
ICD10 via Orphanet 33 C49.9
MedGen 39 C0039101
KEGG 36 H00050
SNOMED-CT via HPO 65 124975008
UMLS 69 C0039101

Summaries for Sarcoma, Synovial

NIH Rare Diseases : 49 Synovial sarcoma is a rare and aggressive soft tissue sarcoma. In the early stages of the condition, it may cause no noticeable signs or symptoms. However, as the tumor grows larger, affected people may notice a lump or swelling. In some cases, the tumor can limit range of motion or cause numbness and/or pain if it presses on nearby nerves. Although synovial sarcoma does not have a clearly defined cause, genetic factors are believed to influence the development of this disease. Cells in these tumors are usually characterized by the presence of a translocation involving chromosomes X and 18. This translocation is specific to synovial sarcoma and is often used to diagnose the condition. Treatment generally includes a combination of surgery, radiation therapy and/or chemotherapy. Last updated: 9/10/2015

MalaCards based summary : Sarcoma, Synovial, also known as synovial sarcoma, is related to epithelioid cell synovial sarcoma and biphasic synovial sarcoma, and has symptoms including synovial sarcoma An important gene associated with Sarcoma, Synovial is SSX1 (SSX Family Member 1), and among its related pathways/superpathways are Transcriptional misregulation in cancer and Endometrial cancer. The drugs Doxorubicin and Ifosfamide have been mentioned in the context of this disorder. Affiliated tissues include t cells, lung and bone, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Disease Ontology : 12 A synovium cancer which develops in the synovial membrane of the joints.

OMIM : 53 Synovial sarcomas, which represent approximately 10% of all soft tissue sarcomas, are aggressive spindle cell sarcomas containing in some cases areas of epithelial differentiation. They consistently show a specific t(X;18)(p11.2;q11.2), which usually represents either of 2 gene fusions, SYT (600192)-SSX1 (312820) or SYT-SSX2 (300192), encoding putative transcriptional proteins differing at 13 amino acid positions (summary by Ladanyi et al., 2002). Synovial sarcoma, according to the experience of Enzinger and Weiss (1983), is the fourth most common type of soft tissue sarcoma. It usually develops in adolescents and young adults, is more common in males than in females, and has no racial predilection. (300813)

Wikipedia : 72 A synovial sarcoma (also known as: malignant synovioma) is a rare form of cancer which occurs primarily... more...

Related Diseases for Sarcoma, Synovial

Diseases related to Sarcoma, Synovial via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 159)
# Related Disease Score Top Affiliating Genes
1 epithelioid cell synovial sarcoma 32.5 SSX1 SSX2B
2 biphasic synovial sarcoma 32.3 CDH1 MUC1 SSX1 VIM
3 spindle cell synovial sarcoma 31.5 KIT KRT7 MET SS18 SSX1 SSX2
4 sarcoma 30.3 KIT MDM2 SS18 SSX1 SSX2 SSX2B
5 ewing sarcoma 29.7 IGF1R KIT MDM2 SS18 VIM
6 mediastinum synovial sarcoma 11.1
7 reticular perineurioma 10.6 KIT MUC1
8 lung acinar adenocarcinoma 10.6 CTNNB1 KRT7
9 jejunal cancer 10.6 KIT KRT7
10 childhood hepatocellular carcinoma 10.6 CTNNB1 MET
11 pseudo-meigs syndrome 10.6 CALB2 CDH1
12 cervical adenoma malignum 10.6 HMGA2 KRT7
13 middle ear adenoma 10.6 KRT7 MUC1
14 mast-cell sarcoma 10.6 KIT VIM
15 large intestine adenocarcinoma 10.6 CDH1 CTNNB1 KRT7
16 ovarian fibrothecoma 10.6 CALB2 KIT
17 endosalpingiosis 10.6 KRT7 MUC1
18 linitis plastica 10.6 CDH1 KRT7
19 glandular cystitis 10.6 KRT7 MUC1
20 adenomyoma 10.6 CTNNB1 KRT7 MUC1
21 kidney hemangiopericytoma 10.6 SS18 SSX2B
22 adenoid squamous cell carcinoma 10.6 CDH1 KRT7 VIM
23 ovarian serous cystadenofibroma 10.6 CALB2 MUC1
24 parachordoma 10.6 KRT7 MUC1 VIM
25 malignant peritoneal mesothelioma 10.6 MUC1 VIM
26 nodular hidradenoma 10.6 KRT7 MUC1 VIM
27 eccrine porocarcinoma 10.6 KRT7 MUC1 VIM
28 sclerosing hemangioma 10.5 CTNNB1 KRT7 MUC1
29 gynandroblastoma 10.5 CALB2 VIM
30 lymphoepithelioma-like carcinoma 10.5 CDH1 KRT7 MUC1
31 hidradenoma 10.5 KRT7 MUC1 VIM
32 perivascular epithelioid cell tumor 10.5 KIT MUC1 VIM
33 mucinous cystadenocarcinoma 10.5 KRT7 MUC1 VIM
34 female reproductive endometrioid cancer 10.5 CTNNB1 KRT7
35 lobular neoplasia 10.5 CDH1 CTNNB1 MUC1
36 organ system benign neoplasm 10.5 CTNNB1 KIT KRT7
37 spiradenoma 10.5 KRT7 MUC1 VIM
38 conventional fibrosarcoma 10.5 CTNNB1 KIT MDM2
39 perineurioma 10.5 KIT MUC1 VIM
40 extraskeletal mesenchymal chondrosarcoma 10.5 SSX1 SSX2B
41 papillary tumor of the pineal region 10.5 MUC1 VIM
42 intrahepatic bile duct adenoma 10.5 KRT19 KRT7
43 fibromatosis 10.5 CTNNB1 KIT VIM
44 chondroid chordoma 10.5 CDH1 MUC1 VIM
45 anal gland adenocarcinoma 10.5 KRT19 KRT7
46 malignant ovarian surface epithelial-stromal neoplasm 10.5 CDH1 KRT7 MUC1
47 ovary epithelial cancer 10.5 CDH1 KRT7 MUC1
48 proliferating trichilemmal cyst 10.5 KRT19 KRT7
49 secretory meningioma 10.5 KRT7 MUC1 VIM
50 bile duct mucoepidermoid carcinoma 10.5 KRT7 MUC1

Graphical network of the top 20 diseases related to Sarcoma, Synovial:



Diseases related to Sarcoma, Synovial

Symptoms & Phenotypes for Sarcoma, Synovial

Clinical features from OMIM:

300813

Human phenotypes related to Sarcoma, Synovial:

31
# Description HPO Frequency HPO Source Accession
1 synovial sarcoma 31 HP:0012570

GenomeRNAi Phenotypes related to Sarcoma, Synovial according to GeneCards Suite gene sharing:

25 (show top 50) (show all 63)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 10.29 SSX2 SSX2B
2 Increased shRNA abundance (Z-score > 2) GR00366-A-102 10.29 KIT
3 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.29 VIM
4 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.29 CTNNB1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-113 10.29 CTNNB1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-114 10.29 IGF1R
7 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.29 SSX1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-127 10.29 IGF1R
9 Increased shRNA abundance (Z-score > 2) GR00366-A-146 10.29 VIM
10 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.29 SSX1 SSX2 SSX2B SSX3 SSX4
11 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.29 KIT
12 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.29 KIT
13 Increased shRNA abundance (Z-score > 2) GR00366-A-169 10.29 IGF1R
14 Increased shRNA abundance (Z-score > 2) GR00366-A-170 10.29 KIT
15 Increased shRNA abundance (Z-score > 2) GR00366-A-176 10.29 VIM
16 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.29 VIM CTNNB1 IGF1R
17 Increased shRNA abundance (Z-score > 2) GR00366-A-189 10.29 VIM
18 Increased shRNA abundance (Z-score > 2) GR00366-A-190 10.29 VIM
19 Increased shRNA abundance (Z-score > 2) GR00366-A-197 10.29 CTNNB1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.29 IGF1R
21 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.29 SSX2B SSX3 SSX4 IGF1R
22 Increased shRNA abundance (Z-score > 2) GR00366-A-23 10.29 SSX1
23 Increased shRNA abundance (Z-score > 2) GR00366-A-29 10.29 VIM
24 Increased shRNA abundance (Z-score > 2) GR00366-A-30 10.29 KIT SSX2 SSX2B VIM
25 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.29 KIT
26 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.29 IGF1R
27 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.29 SSX2B SSX3 IGF1R CTNNB1
28 Increased shRNA abundance (Z-score > 2) GR00366-A-49 10.29 SSX4 CTNNB1
29 Increased shRNA abundance (Z-score > 2) GR00366-A-51 10.29 SSX4
30 Increased shRNA abundance (Z-score > 2) GR00366-A-52 10.29 SSX1
31 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.29 SSX1 VIM
32 Increased shRNA abundance (Z-score > 2) GR00366-A-67 10.29 SSX4 CTNNB1
33 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.29 CTNNB1
34 Increased shRNA abundance (Z-score > 2) GR00366-A-74 10.29 CTNNB1 IGF1R
35 Increased shRNA abundance (Z-score > 2) GR00366-A-76 10.29 SSX2 SSX2B SSX3
36 Increased shRNA abundance (Z-score > 2) GR00366-A-78 10.29 SSX3
37 Increased shRNA abundance (Z-score > 2) GR00366-A-79 10.29 CTNNB1
38 Increased shRNA abundance (Z-score > 2) GR00366-A-81 10.29 SSX2 SSX2B
39 Increased shRNA abundance (Z-score > 2) GR00366-A-82 10.29 SSX4
40 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.29 VIM KIT IGF1R
41 Increased shRNA abundance (Z-score > 2) GR00366-A-9 10.29 KIT
42 Increased shRNA abundance (Z-score > 2) GR00366-A-92 10.29 SSX3
43 Increased shRNA abundance (Z-score > 2) GR00366-A-99 10.29 KIT
44 Decreased shRNA abundance (Z-score < -2) GR00366-A-1 10.25 SSX2
45 Decreased shRNA abundance (Z-score < -2) GR00366-A-10 10.25 MET
46 Decreased shRNA abundance (Z-score < -2) GR00366-A-116 10.25 MET
47 Decreased shRNA abundance (Z-score < -2) GR00366-A-117 10.25 SSX4
48 Decreased shRNA abundance (Z-score < -2) GR00366-A-119 10.25 MET
49 Decreased shRNA abundance (Z-score < -2) GR00366-A-134 10.25 SSX2B SSX3 SSX4 VIM
50 Decreased shRNA abundance (Z-score < -2) GR00366-A-150 10.25 MET

MGI Mouse Phenotypes related to Sarcoma, Synovial:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.76 CDH1 CTNNB1 ELF3 IGF1R KIT KRT19
2 embryo MP:0005380 9.61 CDH1 CTNNB1 IGF1R KIT KRT19 MDM2
3 neoplasm MP:0002006 9.17 CDH1 CTNNB1 IGF1R KIT KRT19 MDM2

Drugs & Therapeutics for Sarcoma, Synovial

Drugs for Sarcoma, Synovial (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 131)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
2
Ifosfamide Approved Phase 3,Phase 2,Phase 1 3778-73-2 3690
3
Mechlorethamine Approved, Investigational Phase 3,Phase 2,Phase 1 51-75-2 4033
4
Dacarbazine Approved, Investigational Phase 3,Phase 2 4342-03-4 5351166
5
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
6
Etoposide Approved Phase 3,Phase 2 33419-42-0 36462
7
Carboplatin Approved Phase 3,Phase 2 41575-94-4 10339178 38904 498142
8
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
9
Dactinomycin Approved, Investigational Phase 3,Phase 2 50-76-0 457193 2019
10
Epirubicin Approved Phase 3,Phase 2 56420-45-2 41867
11
Vincristine Approved, Investigational Phase 3,Phase 2 2068-78-2, 57-22-7 5978
12
Gemcitabine Approved Phase 3,Phase 2 95058-81-4 60750
13
Trabectedin Approved, Investigational Phase 3,Phase 2 114899-77-3 108150
14
Idarubicin Approved Phase 3 58957-92-9 42890
15
Cyproheptadine Approved Phase 3 129-03-3 2913
16
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
17
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
18
Docetaxel Approved May 1996, Investigational Phase 3,Phase 2 114977-28-5 148124 9877265
19 Trofosfamide Investigational Phase 3 22089-22-1
20 Alkylating Agents Phase 3,Phase 2,Phase 1
21 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
22 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
23 Isophosphamide mustard Phase 3,Phase 2,Phase 1 0
24 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
25 Antineoplastic Agents, Phytogenic Phase 3,Phase 2
26 Etoposide phosphate Phase 3,Phase 2
27 Anti-Infective Agents Phase 3,Phase 1,Phase 2
28 Antimitotic Agents Phase 3,Phase 2
29 Antirheumatic Agents Phase 3,Phase 2,Phase 1
30 Immunosuppressive Agents Phase 3,Phase 1,Phase 2
31 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
32 Antimetabolites Phase 3,Phase 2,Phase 1
33 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
34 Antiviral Agents Phase 3,Phase 2
35 Anti-Allergic Agents Phase 3
36 Antipruritics Phase 3
37 Dermatologic Agents Phase 3
38 Gastrointestinal Agents Phase 3
39 Histamine Antagonists Phase 3
40 Histamine H1 Antagonists Phase 3
41
Histamine Phosphate Phase 3 51-74-1 65513
42 Neurotransmitter Agents Phase 3
43
Serotonin Phase 3 50-67-9 5202
44 Serotonin Agents Phase 3
45 Serotonin Antagonists Phase 3
46
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
47
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
48
Trastuzumab Approved, Investigational Phase 2 180288-69-1 9903
49
Everolimus Approved Phase 1, Phase 2 159351-69-6 6442177
50
Miconazole Approved, Investigational, Vet_approved Phase 1, Phase 2 22916-47-8 4189

Interventional clinical trials:

(show top 50) (show all 97)

# Name Status NCT ID Phase Drugs
1 Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma Unknown status NCT00334854 Phase 3 doxorubicin hydrochloride;ifosfamide
2 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
3 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
4 Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3 doxorubicin hydrochloride;ifosfamide
5 Surgery With or Without Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Retroperitoneum or Pelvis Completed NCT00091351 Phase 3
6 Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00003052 Phase 3 doxorubicin hydrochloride;etoposide;ifosfamide
7 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
8 Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00061984 Phase 3 doxorubicin hydrochloride;ifosfamide
9 Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
10 A Phase III Trial of Anlotinib in Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma Recruiting NCT03016819 Phase 3 AL 3818;Dacarbazine
11 Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy Recruiting NCT01710176 Phase 3 epirubicin 60 mg/m2/day (days 1, 2) and ifosfamide 3 g/m2/day (days 1, 2, 3);gemcitabine 900 mg/m2 (days 1 and 8) and docetaxel 75 mg/m2 (day 8);trabectedin 1.3 mg/m2;high-dose ifosfamide 14 g/m2, given in in 14 days;etoposide 150 mg/m2/day (days 1, 2, 3) and ifosfamide 3g/m2/day (days 1, 2, 3);gemcitabine 1800 mg/m2 (day 1) and dacarbazine 500 mg/m2 (day 1)
12 Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Recruiting NCT02180867 Phase 2, Phase 3 Doxorubicin Hydrochloride;Ifosfamide;Pazopanib Hydrochloride
13 Trial for Localised High-risk Rhabdomyosarcoma and Rhabdomyosarcoma-like Soft Tissue Sarcoma Recruiting NCT00876031 Phase 3 trofosfamide, idarubicin, etoposide
14 Randomised Trial of Volume of Post-operative Radiotherapy Given to Adult Patients With eXtremity Soft Tissue Sarcoma Active, not recruiting NCT00423618 Phase 3
15 Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma Terminated NCT01189253 Phase 2, Phase 3 doxorubicin hydrochloride;trabectedin
16 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
17 Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma Unknown status NCT00410462 Phase 2 brostallicin;doxorubicin hydrochloride
18 Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma Unknown status NCT00003718 Phase 2 temozolomide
19 Gefitinib in Treating Patients With Locally Advanced or Metastatic Synovial Sarcoma Completed NCT00052754 Phase 2 gefitinib
20 Trastuzumab in Treating Patients With Locally Advanced or Metastatic Synovial Sarcoma Completed NCT00104949 Phase 2
21 Everolimus in Combination With Imatinib Mesylate in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Soft Tissue Sarcoma Completed NCT01281865 Phase 1, Phase 2 everolimus;imatinib mesylate
22 A Study of R1507 in Participants With Recurrent or Refractory Sarcoma Completed NCT00642941 Phase 2 RG1507
23 A Five-Tier, Open-Label Study of IMC-A12 in Advanced Sarcoma Completed NCT00668148 Phase 2
24 Sorafenib and Dacarbazine in Soft Tissue Sarcoma Completed NCT00837148 Phase 2 Sorafenib and Dacarbazine
25 Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-treatment Failure Completed NCT01136499 Phase 2 LBH589 (Panobinostat®)
26 Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors Completed NCT00831844 Phase 2
27 Activity of Trabectedin or Gemcitabine + Docetaxel in Uterine Leiomyosarcoma Completed NCT02249702 Phase 2 gemcitabine + docetaxel;trabectedin
28 Safety and Efficacy Study of REOLYSIN® in the Treatment of Bone and Soft Tissue Sarcomas Metastatic to the Lung Completed NCT00503295 Phase 2
29 Ixabepilone in Treating Young Patients With Refractory Solid Tumors Completed NCT00331643 Phase 2 ixabepilone
30 Bevacizumab and Radiation Therapy for Sarcomas Completed NCT00356031 Phase 2 Bevacizumab
31 Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood Completed NCT00030667 Phase 2 imatinib mesylate
32 Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01154452 Phase 1, Phase 2 Gamma-Secretase Inhibitor RO4929097;Vismodegib
33 Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma Completed NCT00245102 Phase 2 sorafenib tosylate
34 Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma Completed NCT00112463 Phase 2 romidepsin
35 Pazopanib In Patients With Relapsed Or Refractory Soft Tissue Sarcoma Completed NCT00297258 Phase 2 pazopanib
36 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2 Imatinib mesylate
37 Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma Completed NCT00949325 Phase 1, Phase 2 temsirolimus (Torisel) plus liposomal doxorubicin (Doxil)
38 BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors Completed NCT00526149 Phase 2 BI 2536
39 Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas Completed NCT00474994 Phase 2 sunitinib malate
40 Soblidotin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00064220 Phase 2 soblidotin
41 Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00003939 Phase 2 trabectedin
42 STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma Completed NCT00006357 Phase 1, Phase 2 imatinib mesylate
43 Perifosine in Treating Patients With Metastatic or Locally Advanced Soft Tissue Sarcoma Completed NCT00053794 Phase 2 perifosine
44 Brostallicin in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00041249 Phase 2 brostallicin
45 Exatecan Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00041236 Phase 2 exatecan mesylate
46 Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma Completed NCT00031915 Phase 2 imatinib mesylate
47 Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors Completed NCT00025441 Phase 2 carboplatin;cyclophosphamide;doxorubicin hydrochloride;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
48 DHEA in Synovial Sarcoma Patients Recruiting NCT02683148 Phase 1, Phase 2 DHEA
49 Study of TBI-1301 (NY-ESO-1 T Cell Receptor Gene Transduced Autologous T Lymphocytes) in Patients With Synovial Sarcoma Recruiting NCT03250325 Phase 1, Phase 2 Cyclophosphamide
50 Whole Lung IMRT in Children and Adults With Synovial Sarcoma and Lung Metastases Recruiting NCT02181829 Phase 2

Search NIH Clinical Center for Sarcoma, Synovial

Cochrane evidence based reviews: sarcoma, synovial

Genetic Tests for Sarcoma, Synovial

Genetic tests related to Sarcoma, Synovial:

# Genetic test Affiliating Genes
1 Synovial Sarcoma 28 SSX1 SSX2

Anatomical Context for Sarcoma, Synovial

MalaCards organs/tissues related to Sarcoma, Synovial:

38
T Cells, Lung, Bone, Brain, Testis, Testes

Publications for Sarcoma, Synovial

Articles related to Sarcoma, Synovial:

(show top 50) (show all 832)
# Title Authors Year
1
Synovial sarcoma mimicking a thoracic dumbell schwannoma- a case report. ( 29446979 )
2018
2
Extracellular vesicle-encapsulated microRNA-761 enhances pazopanib resistance in synovial sarcoma. ( 29191657 )
2018
3
The potential of the CMB305 vaccine regimen to target NY-ESO-1 and improve outcomes for synovial sarcoma and myxoid/round cell liposarcoma patients. ( 29280411 )
2018
4
Primary Gastric Synovial Sarcoma Mimicking a Gastrointestinal Stromal Tumor (GIST) : Gastric Synovial Sarcoma. ( 29313287 )
2018
5
Establishment and characterization of the NCC-SS1-C1 synovial sarcoma cell line. ( 29450702 )
2018
6
PAX8-positive Biphasic Synovial Sarcoma Expressing Hormonal Receptors. ( 28248726 )
2017
7
TLE-1-Positive Angiomatoid Fibrous Histiocytoma Mimicking Synovial Sarcoma. ( 28248724 )
2017
8
Correction: Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma. ( 28085948 )
2017
9
Primary Cystic Pleuropulmonary Synovial Sarcoma Presenting as Recurrent Pneumothorax. ( 28868028 )
2017
10
Monophasic synovial sarcoma of the greater omentum: case report and review of literature. ( 28660813 )
2017
11
The prognostic impact of SYT-SSX fusion type and histological grade in pediatric patients with synovial sarcoma treated according to the CWS (Cooperative Weichteilsarkom Studie) trials. ( 27621063 )
2017
12
Biphasic synovial sarcoma of the epiglottis: Case report and literature review. ( 28689931 )
2017
13
Cytologic features of primary monophasic synovial sarcoma of the thyroid gland. ( 29259650 )
2017
14
Metachronuous Synovial Sarcoma After Treatment of Mixed Germ Cell Tumor in a Child of Complet Gonodal Dysgenesis. ( 28836496 )
2017
15
Primary Synovial Sarcoma of External Auditory Canal: A Case Report. ( 28948118 )
2017
16
Whorling cellular perineurioma: A previously undescribed variant closely mimicking monophasic fibrous synovial sarcoma. ( 28325366 )
2017
17
Cancer-testis antigen expression in synovial sarcoma: NY-ESO-1, PRAME, MAGEA4, and MAGEA1. ( 27993576 )
2017
18
ATR Is a Therapeutic Target in Synovial Sarcoma. ( 29038346 )
2017
19
Diagnostic Approach to Synovial Sarcoma of the Head and Neck Illustrated by Two Cases Arising in the Face and Oral Cavity. ( 27195266 )
2016
20
Cardiac metastasis of synovial sarcoma presenting with superior vena cava syndrome. ( 27282684 )
2016
21
Synovial sarcoma presenting as colonic intussusception in a child. ( 27572305 )
2016
22
Prognostic significance of FOXM1 expression and antitumor effect of FOXM1 inhibition in synovial sarcomas. ( 27439614 )
2016
23
Essential role of mitogen-activated protein kinases in IL-17A-induced MMP-3 expression in human synovial sarcoma cells. ( 26850593 )
2016
24
Intra-abdominal synovial sarcoma. ( 27198201 )
2016
25
Expression of PSMA in tumor neovasculature of high grade sarcomas including synovial sarcoma, rhabdomyosarcoma, undifferentiated sarcoma and MPNST. ( 28002805 )
2016
26
The fusion protein SS18-SSX1 employs core Wnt pathway transcription factors to induce a partial Wnt signature in synovial sarcoma. ( 26905812 )
2016
27
Primary pleuropulmonary synovial sarcoma mimicking a carcinoid tumor: Case report and literature review. ( 27257447 )
2016
28
Primary pulmonary monophasic synovial sarcoma: Evading diagnosis. ( 26612959 )
2016
29
Role, timing and technique of radiotherapy in pediatric pleuropulmonary synovial sarcoma. ( 27659844 )
2016
30
The interaction of hepatoma-derived growth factor and I^-catenin promotes tumorigenesis of synovial sarcoma. ( 26842923 )
2016
31
Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma. ( 27391784 )
2016
32
Monophasic synovial sarcoma of posterior pharyngeal wall: a rare case report with unique reconstruction using lateral trapezius flap. ( 27328959 )
2016
33
Functional and therapeutic relevance of hepatocyte growth factor/c-MET signaling in synovial sarcoma. ( 27779808 )
2016
34
Occult primary pulmonary synovial sarcoma presenting as recurrent spontaneous pneumothorax and explosive progression. ( 27995774 )
2016
35
Intravascular Biphasic Synovial Sarcoma: The Beneficial Role of Adjuvant Treatment Approach in the Pre-metastatic Stage. ( 27190730 )
2016
36
Biphasic synovial sarcoma with prominent cavernous hemangioma-like stroma. ( 27988941 )
2016
37
The diagnostic utility of reduced immunohistochemical expression of SMARCB1 in synovial sarcomas: a validation study. ( 26520417 )
2016
38
Primary Mediastinal Synovial Sarcoma with subsequent development of Primary Adenoid Cystic Carcinoma of Lung presenting as superior vena cava syndrome. ( 26992072 )
2016
39
Gastric ulcer that turned out to be metastasis of a synovial sarcoma: A case report and literature review. ( 28087966 )
2016
40
Synovial Sarcoma Mimicking Myositis Ossificans. ( 27595081 )
2016
41
Sudden onset of paraplegia secondary to an unusual presentation of pediatric synovial sarcoma. ( 27444286 )
2016
42
Synovial sarcoma of the hypopharynx in a pediatric patient: Case report. ( 27649458 )
2016
43
A Tumour in Disguise in the Right Palm- Monophasic Synovial Sarcoma. ( 27437233 )
2016
44
Primary Synovial Sarcoma of the Kidney with Inferior Vena Caval Thrombus. ( 27651698 )
2016
45
Transducer-like enhancer of split 1 (TLE1) expression as a diagnostic immunohistochemical marker for synovial sarcoma and its association with morphological features. ( 27568668 )
2016
46
Response to pazopanib in two pediatric patients with pretreated relapsing synovial sarcoma. ( 27647230 )
2016
47
Monosomy 22 and partial loss of INI1 expression in a biphasic synovial sarcoma with an Ewing sarcoma-like poorly differentiated component: Report of a case. ( 27118264 )
2016
48
Synovial sarcoma in children and adolescents: the European Pediatric Soft Tissue Sarcoma Study Group prospective trial (EpSSG NRSTS 2005). ( 25488687 )
2015
49
Primary Mediastinal Synovial Sarcoma Presenting as Superior Vena Cava Syndrome: A Rare Case Report and Review of the Literature. ( 26101678 )
2015
50
Detection of Rare Variant of SS18-SSX1 Fusion Gene and Mutations of Important Cancer-Related Genes in Synovial Sarcoma of the Lip: Gene Analyses of a Case and Literature Review. ( 25959879 )
2015

Variations for Sarcoma, Synovial

Cosmic variations for Sarcoma, Synovial:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM480 HRAS soft tissue,lower leg,synovial sarcoma,NS c.34G>A p.G12S 8
2 COSM1745010 MYOD1 soft tissue,upper leg,rhabdomyosarcoma,spindle cell c.365T>G p.L122R 4
3 COSM33732 IDH2 soft tissue,upper leg,haemangioma,spindle cell c.515G>T p.R172M 4

Copy number variations for Sarcoma, Synovial from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 120197 18 21850214 21924609 Translate SS18 Synovial sarcoma

Expression for Sarcoma, Synovial

Search GEO for disease gene expression data for Sarcoma, Synovial.

Pathways for Sarcoma, Synovial

Pathways related to Sarcoma, Synovial according to KEGG:

36
# Name Kegg Source Accession
1 Transcriptional misregulation in cancer hsa05202

Pathways related to Sarcoma, Synovial according to GeneCards Suite gene sharing:

(show all 15)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.82 CDH1 CTNNB1 IGF1R KIT MDM2 MET
2
Show member pathways
12.54 CDH1 CTNNB1 IGF1R KIT MET
3
Show member pathways
12.47 CDH1 CTNNB1 IGF1R KIT MET
4 12.46 CDH1 CTNNB1 IGF1R KIT MDM2 MET
5
Show member pathways
12.3 CDH1 CTNNB1 MDM2 MUC1
6
Show member pathways
12.27 CTNNB1 IGF1R MDM2 MET
7 12.21 CDH1 KRT19 KRT7 MUC1 VIM
8 12.01 CTNNB1 IGF1R MDM2 MET
9
Show member pathways
11.68 CDH1 CTNNB1 MET
10 11.55 CDH1 CTNNB1 MET
11 11.49 HMGA2 IGF1R MDM2 MET SS18 SSX1
12 11.31 CDH1 CTNNB1 IGF1R MET
13 11.15 CDH1 CTNNB1 MET
14 10.86 CDH1 CTNNB1 IGF1R MET
15 10.64 CDH1 CTNNB1

GO Terms for Sarcoma, Synovial

Cellular components related to Sarcoma, Synovial according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 apical junction complex GO:0043296 9.16 CDH1 CTNNB1
2 catenin complex GO:0016342 8.96 CDH1 CTNNB1
3 flotillin complex GO:0016600 8.62 CDH1 CTNNB1

Biological processes related to Sarcoma, Synovial according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transcription, DNA-templated GO:0006351 9.97 CTNNB1 ELF3 HMGA2 SS18 SSX1 SSX2
2 positive regulation of gene expression GO:0010628 9.65 CTNNB1 HMGA2 KIT MDM2 VIM
3 cellular response to indole-3-methanol GO:0071681 9.16 CDH1 CTNNB1
4 entry of bacterium into host cell GO:0035635 9.13 CDH1 CTNNB1 MET
5 negative regulation of nucleic acid-templated transcription GO:1903507 9.02 SSX1 SSX2 SSX2B SSX3 SSX4

Molecular functions related to Sarcoma, Synovial according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.91 CDH1 CTAG1B CTNNB1 ELF3 HMGA2 IGF1R
2 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.33 IGF1R KIT MET
3 transcription corepressor activity GO:0003714 9.02 SSX1 SSX2 SSX2B SSX3 SSX4

Sources for Sarcoma, Synovial

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....